Atlas Trials

Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)

Clinical trial NCT04469465 · COMPLETED

Trial details

NCT number
NCT04469465
Sponsor
Alexion Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Paroxysmal Nocturnal Hemoglobinuria
Start date
2020-12-16
Primary completion
2022-06-29
Enrollment
86

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.